Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Research Biosimilar

Research Grade Solanezumab

Catalog #:   DHC12505 Specific References (100) DATASHEET
Host species: Humanized
Isotype: IgG1-kappa
Applications: Research Grade Biosimilar
Expression system: Mammalian Cells
Overview

Catalog No.

DHC12505

Description

Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the Aβ peptide. It recognizes soluble monomeric, not fibrillar, Aβ. Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer’s disease.

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Humanized

Isotype

IgG1-kappa

Clonality

Monoclonal

Target

AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59, AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal fragment, Amyloid-beta precursor protein, Amyloid precursor protein, Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein, Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF, Gamma-CTF(57), AICD-50

Concentration

1.8 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P05067

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

LY2062430, CAS: 955085-14-0

Clone ID

Solanezumab

Data Image
  • SDS-PAGE
    SDS PAGE for Solanezumab
  • SEC-HPLC
    The purity of this product is >95% as determined by SEC-HPLC.
References

Trial of Solanezumab for Mild Dementia Due to Alzheimer's Disease, PMID: 29365294

Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients, PMID: 26238576

Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease, PMID: 24450890

Solanezumab for Alzheimer's disease, PMID: 21504387

The amyloid hypothesis of Alzheimer's disease at 25 years, PMID: 27025652

Solanezumab for the treatment of mild-to-moderate Alzheimer's disease, PMID: 22288451

Central pharmacodynamic activity of solanezumab in mild Alzheimer's disease dementia, PMID: 30511011

Bapineuzumab and solanezumab for Alzheimer's disease: is the 'amyloid cascade hypothesis' still alive?, PMID: 23574434

Grasping at straws: the failure of solanezumab to modify mild Alzheimer's disease, PMID: 30376649

Solanezumab: too late in mild Alzheimer's disease?, PMID: 28102152

Solanezumab and the amyloid hypothesis for Alzheimer's disease, PMID: 28034844

Anti-amyloid-β protein agents for the treatment of Alzheimer's disease: an update on emerging drugs, PMID: 32772738

Pathways Connecting Late-Life Depression and Dementia, PMID: 32231570

Kinetic fingerprints differentiate the mechanisms of action of anti-Aβ antibodies, PMID: 32989305

Passive antiamyloid immunotherapy for Alzheimer's disease, PMID: 32040044

The potential of solanezumab and gantenerumab to prevent Alzheimer's disease in people with inherited mutations that cause its early onset, PMID: 29037101

Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease, PMID: 29910719

Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β, PMID: 29686315

Amyloid-related imaging abnormalities from trials of solanezumab for Alzheimer's disease, PMID: 27239538

Lessons Learnt from the Second Generation of Anti-Amyloid Monoclonal Antibodies Clinical Trials, PMID: 33321511

Quantile regression to characterize solanezumab effects in Alzheimer's disease trials, PMID: 29067306

The Integrated Alzheimer's Disease Rating Scale (iADRS) Findings from the EXPEDITION3 Trial, PMID: 29616706

Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years, PMID: 29854931

Efficacy and safety of anti-amyloid- β immunotherapy for Alzheimer's disease: a systematic review and network meta-analysis, PMID: 29296624

Sixty seconds on . . . solanezumab, PMID: 27899350

The preclinical Alzheimer cognitive composite: measuring amyloid-related decline, PMID: 24886908

Alzheimer disease: Solanezumab-prospects for meaningful interventions in AD?, PMID: 26526537

Chemical and neuropathological analyses of an Alzheimer's disease patient treated with solanezumab, PMID: 27725918

The Failure of Solanezumab - How the FDA Saved Taxpayers Billions, PMID: 28467878

A Combined Measure of Cognition and Function for Clinical Trials: The Integrated Alzheimer's Disease Rating Scale (iADRS), PMID: 27019841

Comparison of pharmacokinetics, pharmacodynamics, safety, and tolerability of the amyloid β monoclonal antibody solanezumab in Japanese and white patients with mild to moderate alzheimer disease, PMID: 22134132

Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N‑truncated Abeta in sporadic Alzheimer disease cases and mouse models, PMID: 26467270

Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease, PMID: 29405226

Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis, PMID: 31831056

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer's disease, PMID: 34155411

Delayed-start analysis for demonstrating disease modification of solanezumab, PMID: 29854938

Anti-Aβ agents for mild to moderate Alzheimer's disease: systematic review and meta-analysis, PMID: 33046560

Validation of assays for measurement of amyloid-β peptides in cerebrospinal fluid and plasma specimens from patients with Alzheimer's disease treated with solanezumab, PMID: 23302661

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716688

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716689

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24724181

Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease, PMID: 24716687

Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trials, PMID: 28365320

Safety and biomarker effects of solanezumab in patients with Alzheimer's disease, PMID: 22672770

Recent trial shows that solanezumab has disease modifying effects, PMID: 26318507

[Immunotherapy for Alzheimer's disease], PMID: 26815584

Early Dementia Screening, PMID: 26838803

Need for a trial of solanezumab in mild Alzheimer's disease, PMID: 26330409

Mutual population-shift driven antibody-peptide binding elucidated by molecular dynamics simulations, PMID: 31996730

Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: the point of no return?, PMID: 24981190

Immunohistochemical evaluation of a trial of gantenerumab or solanezumab in dominantly inherited Alzheimer disease., PMID:40459787

Changes in Daily Functioning in Association With Tau and Amyloid Among Unimpaired Older Adults With and Without Elevated Amyloid., PMID:40440591

The Efficacy of Anti-amyloid Monoclonal Antibodies in Early Alzheimer's Dementia: A Systematic Review., PMID:40346804

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial., PMID:40120616

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU Trial., PMID:39974075

Second-generation anti-amyloid monoclonal antibodies for Alzheimer's disease: current landscape and future perspectives., PMID:39865265

A systematic review of the efficacy and safety of anti-amyloid beta monoclonal antibodies in treatment of Alzheimer's disease., PMID:39432414

Anti-amyloid β Antibody Therapies for Alzheimer's Disease: Association between the Target of Amyloid β Aggregates and the Clinical Efficacy of Anti-amyloid β Antibody., PMID:39401909

Limitations and potential strategies of immune checkpoint blockade in age-related neurodegenerative disorders., PMID:39313800

Benefits and risks of FDA-approved amyloid-targeting antibodies for treatment of early Alzheimer's disease: Navigating clinician-patient engagement., PMID:39306695

Greater White Matter Hyperintensity Volume Is Associated with the Number of Microhemorrhages in Preclinical Alzheimer's Disease., PMID:39044495

Change in Digital Cognitive Test Performance between Solanezumab and Placebo Groups in Preclinical Alzheimer's Disease: Secondary Analyses from the A4 Study., PMID:39044493

Longitudinal Trajectories of the Cognitive Function Index in the A4 Study., PMID:39044492

Longitudinal Phospho-tau217 Predicts Amyloid Positron Emission Tomography in Asymptomatic Alzheimer's Disease., PMID:39044490

Characterizing Clinical Progression in Cognitively Unimpaired Older Individuals with Brain Amyloid: Results from the A4 Study., PMID:39044489

Amyloid and Tau Prediction of Cognitive and Functional Decline in Unimpaired Older Individuals: Longitudinal Data from the A4 and LEARN Studies., PMID:39044488

Engineered Antibodies to Improve Efficacy against Neurodegenerative Disorders., PMID:38928395

Beyond lecanemab: Examining Phase III potential in Alzheimer's therapeutics., PMID:38868475

A Review of Recent Advances in the Management of Alzheimer's Disease., PMID:38756263

Amyloid-beta antibody binding to cerebral amyloid angiopathy fibrils and risk for amyloid-related imaging abnormalities., PMID:38740836

Passive immunotherapy for Alzheimer's disease: challenges & future directions., PMID:38715084

Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU): Trial Satisfaction and Attitudes towards Future Clinical Trials., PMID:38706272

Lessons learned from the failure of solanezumab as a prospective treatment strategy for Alzheimer's disease., PMID:38685682

Downstream Biomarker Effects of Gantenerumab or Solanezumab in Dominantly Inherited Alzheimer Disease: The DIAN-TU-001 Randomized Clinical Trial., PMID:38683602

Correction: Abeta targets of the biosimilar antibodies of Bapineuzumab, Crenezumab, Solanezumab in comparison to an antibody against N-truncted Abeta in sporadic Alzheimer disease cases and mouse models., PMID:38526686

Comparative Efficacy and Safety of Monoclonal Antibodies for Cognitive Decline in Patients with Alzheimer's Disease: A Systematic Review and Network Meta-Analysis., PMID:38429615

More failure with solanezumab - this time in preclinical Alzheimer's disease., PMID:38414336

Examining amyloid reduction as a surrogate endpoint through latent class analysis using clinical trial data for dominantly inherited Alzheimer's disease., PMID:38400532

Development of amyloid beta-directed antibodies against Alzheimer's disease: Twists and turns., PMID:38220210

Navigating the dementia landscape: Biomarkers and emerging therapies., PMID:38215913

Patients with geriatric syndromes and anti-amyloid therapies: lack of consideration? An exploratory analysis of the literature., PMID:37881360

Knowledge-guided Deep Temporal Clustering for Alzheimer's Disease Subtypes in Completed Clinical Trials., PMID:37873161

Monoclonal Antibody Treatments for Alzheimer's Disease: Aducanumab and Lecanemab., PMID:39726673

Comparative Study of Safety and Efficacy of Angiotensin-Receptor Blockers and Anti Amyloid-ß Monoclonal Antibodies for the Treatment of Alzheimer's Disease: A Systematic Review., PMID:37746412

Trial of Solanezumab in Preclinical Alzheimer's Disease., PMID:37458272

Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based meta-analysis., PMID:37423541

Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force., PMID:37357282

APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials., PMID:37204338

Mechanism Exploration of Amyloid-β-42 Disaggregation by Single-Chain Variable Fragments of Alzheimer's Disease Therapeutic Antibodies., PMID:37176076

Longitudinal head-to-head comparison of 11C-PiB and 18F-florbetapir PET in a Phase 2/3 clinical trial of anti-amyloid-β monoclonal antibodies in dominantly inherited Alzheimer's disease., PMID:37017737

Targeting amyloid β in Alzheimer's disease: Meta-analysis of low-dose solanezumab in Alzheimer's disease with mild dementia studies., PMID:36946603

Investigational treatments for neurodegenerative diseases caused by inheritance of gene mutations: lessons from recent clinical trials., PMID:36751779

A combined physiologically-based pharmacokinetic and quantitative systems pharmacology model for modeling amyloid aggregation in Alzheimer's disease., PMID:36632701

Review of Alzheimer's disease drugs and their relationship with neuron-glia interaction., PMID:36593897

Evaluation of dose-dependent treatment effects after mid-trial dose escalation in biomarker, clinical, and cognitive outcomes for gantenerumab or solanezumab in dominantly inherited Alzheimer's disease., PMID:36348972

Quantitative systems pharmacology model of the amyloid pathway in Alzheimer's disease: Insights into the therapeutic mechanisms of clinical candidates., PMID:36281062

Amyloid-Related Imaging Abnormalities in the DIAN-TU-001 Trial of Gantenerumab and Solanezumab: Lessons from a Trial in Dominantly Inherited Alzheimer Disease., PMID:36151869

The Future of AD Clinical Trials with the Advent of Anti-Amyloid Therapies: An CTAD Task Force Report., PMID:35841240

Magnetic resonance imaging measures of brain volumes across the EXPEDITION trials in mild and moderate Alzheimer's disease dementia., PMID:35783453

Avoid or Embrace? Practice Effects in Alzheimer's Disease Prevention Trials., PMID:35783127

Datasheet

Document Download

Research Grade Solanezumab.pdf

 

$ 328
Product specifications
100 μg 328 1 mg 1314

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Research Grade Solanezumab [DHC12505]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only